Skip to content

Andrea Coccoglioniti

Department of Clinical and Experimental Medicine, Section of Psychiatry, University of Pisa, Pisa, Italy.

1 paper in the library · 4 citations · publishing 2025

Papers

Evaluating the value and risks of psychedelics for psychiatric medicine: a clinical perspective.

Expert review of neurotherapeutics February 1, 2025 Donatella Marazziti, Francesco Weiss, Riccardo Gurrieri et al. 4 citations

After decades of neglect, psychedelics are again being studied for clinical use, but the current enthusiasm risks overstating their benefits and downplaying their harms. The authors review the literature to give a balanced account of both therapeutic potential and risks. Psychedelics show promise for many conditions and appear to have limited risk of abuse or dependence when given under controlled conditions by trained staff. However, many questions remain, and more research is needed to identify which patients and conditions will benefit and which face greater risk of adverse effects.